Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Atara Biotherapeutics's profit margin for the twelve months ending Sep 30, 2026 was -368.6%. For fiscal 2025 it was 27.1%, against -66.2% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.1% | +93.3 |
| FY2024 | Dec 31, 2024 | -66.2% | +3154.6 |
| FY2023 | Dec 31, 2023 | -3220.9% | −2861.8 |
| FY2022 | Dec 31, 2022 | -359.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -182.1% | −57.5 |
| Q2 FY2026 | Jun 30, 2026 | -767.3% | −780.9 |
| Q1 FY2026 | Mar 31, 2026 | -803.3% | −842.0 |
| Q4 FY2025 | Dec 31, 2025 | -213.5% | −174.8 |
| Q3 FY2025 | Sep 30, 2025 | -124.6% | −70.1 |
| Q2 FY2025 | Jun 30, 2025 | 13.6% | +80.1 |
| Q1 FY2025 | Mar 31, 2025 | 38.7% | +154.8 |
| Q4 FY2024 | Dec 31, 2024 | -38.8% | +1382.9 |
| Q3 FY2024 | Sep 30, 2024 | -54.5% | +3210.1 |
| Q2 FY2024 | Jun 30, 2024 | -66.5% | +7363.8 |
| Q1 FY2024 | Mar 31, 2024 | -116.1% | +5982.7 |
| Q4 FY2023 | Dec 31, 2023 | -1421.7% | +32321.3 |
| Q3 FY2023 | Sep 30, 2023 | -3264.6% | −1378.7 |
| Q2 FY2023 | Jun 30, 2023 | -7430.3% | −7466.1 |
| Q1 FY2023 | Mar 31, 2023 | -6098.8% | −4894.2 |
| Q4 FY2022 | Dec 31, 2022 | -33743.0% | – |
| Q3 FY2022 | Sep 30, 2022 | -1885.9% | – |
| Q2 FY2022 | Jun 30, 2022 | 35.8% | – |
| Q1 FY2022 | Mar 31, 2022 | -1204.6% | – |
See a number that looks wrong?